within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01A_AgentsAgainstAmoebiasisAndOtherProtozoalDiseases.P01AX10_Fumagillin;

model Fumagillin
  extends Pharmacolibrary.Drugs.ATC.P.P01AX10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>P01AX10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fumagillin is an antimicrobial compound originally derived from the fungus Aspergillus fumigatus. It exhibits activity against microsporidia and has also shown anti-angiogenic properties. Fumagillin has been historically used for the treatment of microsporidial infections, especially in immunocompromised patients, and as an antiparasitic in veterinary medicine, particularly for honeybee Nosema disease. It is not an approved drug for human use in most countries today.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies are available. Pharmacokinetic parameters are estimated based on physicochemical properties and available preclinical data.</p><h4>References</h4><ol><li><p>Kalsi, H, &amp; Grewal, RK (2015). Interaction of mouse intestinal P-glycoprotein with oral antidiabetic drugs and its inhibitors. <i>Indian journal of experimental biology</i> 53(9) 611–616. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26548081/&quot;>https://pubmed.ncbi.nlm.nih.gov/26548081</a></p></li><li><p>Dezube, BJ, et al., &amp; Gill, PS (1998). Fumagillin analog in the treatment of Kaposi&#x27;s sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 16(4) 1444–1449. DOI:<a href=&quot;https://doi.org/10.1200/JCO.1998.16.4.1444&quot;>10.1200/JCO.1998.16.4.1444</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9552050/&quot;>https://pubmed.ncbi.nlm.nih.gov/9552050</a></p></li><li><p>Arico-Muendel, CC, et al., &amp; White, KF (2013). Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 41(4) 814–826. DOI:<a href=&quot;https://doi.org/10.1124/dmd.112.048355&quot;>10.1124/dmd.112.048355</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23355637/&quot;>https://pubmed.ncbi.nlm.nih.gov/23355637</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fumagillin;
